FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.252,88 +167,08 (+0,44%) Nasdaq
15.933,51 +321,75 (+2,06%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
84,03 +0,46 (+0,55%) Bitcoin EUR
59.549,57 -460,45 (-0,77%)
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
- GlobeNewswire
Corbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701
CRB-701 demonstrates a differentiated nonclinical profile relative to enfortumab vedotinEarly dose escalation clinical data supports differentiating features established pre-clinicallyThe company on schedule to initiate its US study in Q1-2024 NORWOOD, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced that a poster characterizing the pre-clinical validation of CRB-701, a next ge
- GlobeNewswire
Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert’ Series (Session 2) on CRB-701 on October 10, 2023
NORWOOD, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that it will host a Virtual ‘Meet the Expert’ event on the development of a next generation Nectin-4 antibody drug conjugate, focusing on opportunities and challenges for CRB-701, on Tuesday, October 10, 2023 at 10:30am ET. To register for the webinar, click here. The event will feature several Oncology experts Daniel P.
